May 25, 9:11 PM EDT
Media & Culture
Gilead Sciences' HIV drug regimen meets mid-stage goal
By IBT Staff Reporter on 01/06/10 AT 2:44 PM
Gilead Sciences Inc (GILD.O) said top-line results of a mid-stage study showed that its experimental drug regimen to treat HIV infection met the main goal, sending its shares up as much as 4 percent.